Clinical trials: Prostate Cancer Metastatic Disease
Metastatic Prostate Cancer
Study of AZD0754 in Participants With Metastatic Prostate Cancer
The purpose of this study is to evaluate the safety, tolerability, and antitumour activity of AZD0754 CAR T-cell therapy in participants with metastatic prostate cancer.
- Trial name
- APOLLO (NCT06267729)
- Testing
- AZD0754, AZD2287
- Where
- 15 sites in United States, Australia and 1 more
- Volunteers
- 60 people
- Sponsor
- AstraZeneca
Prostate Cancer
S0354, Anti-IL-6 Chimeric Monoclonal Antibody in Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy
RATIONALE: Monoclonal antibodies, such as anti-IL-6 chimeric monoclonal antibody, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00433446
- Testing
- CNTO 328
- Where
- 123 sites in United States
- Volunteers
- 62 people
- Sponsor
- SWOG Cancer Research Network
Prostate Cancer
Isotretinoin, Interferon Alfa-2b, Docetaxel, and Estramustine in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy
RATIONALE: Isotretinoin may help prostate cancer cells become more like normal cells, and to grow and spread more slowly. Interferon alfa-2b may interfere with the growth of tumor cells.
- Trial name
- NCT00176527
- Testing
- recombinant interferon alfa-2b, docetaxel, estramustine phosphate sodium
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Medicine and Dentistry of New Jersey
Prostate Cancer
BMTP-11 in Patients With Castrate-Resistant Prostate Cancer With Bone Mets
The goal of this clinical research study is find the highest tolerable dose of BMTP-11 when given to patients with prostate cancer that has spread. The safety of this drug will also be studied.
- Trial name
- NCT00872157
- Testing
- BMTP-11
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- M.D. Anderson Cancer Center
Prostate Cancer
PSMA Response in Metastasized Hormone Sensitive Prostate Cancer
PSMA-PET/CT response measurements after LHRH agonist and upfront therapy in men diagnosed with de novo metastasized hormonal sensitive prostate cancer.
- Trial name
- PET-MaN (NCT05161728)
- Testing
- PSMA-PET/CT
- Where
- 4 sites in Netherlands
- Volunteers
- 150 people
- Sponsor
- Roderick van den Bergh
Prostate Cancer
Bicalutamide and Ridaforolimus in Men With Prostate Cancer (MK-8669-002)
This study will look to see if the combination of ridaforolimus and bicalutamide works better than placebo and bicalutamide in men with prostate cancer.
- Trial name
- NCT00777959
- Testing
- ridaforolimus (MK8669), open-label ridaforolimus (MK8669)
- Volunteers
- 22 people
- Sponsor
- Merck Sharp & Dohme LLC
Prostate Cancer, Prostate Cancer Adenocarcinoma
Immediate Prostatectomy vs. Cabozantinib Followed by Prostatectomy in Men With High-Risk Prostate Cancer
This is a prospective, randomized, open-label, phase II trial of cabozantinib in subjects with untreated, high risk prostate cancer undergoing radical prostatectomy. This multicenter study will enroll 30 subjects.
- Conditions
- Prostate Cancer, Prostate Cancer Adenocarcinoma, Non-Metastatic
- Trial name
- SPARC (NCT03964337)
- Testing
- Cabozantinib, Radical Prostatectomy
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Duke University
Hormone Refractory Prostate Cancer
A Study Comparing AT-101 in Combination With Docetaxel and Prednisone Versus Docetaxel and Prednisone in Men With Chemotherapy-Naïve Metastatic Hormone Refractory Prostate Cancer (HRPC)
This is a randomized, double-blind, placebo-controlled, multinational Phase 2 study to evaluate and compare oral AT-101 in combination with docetaxel and prednisone versus docetaxel and prednisone plus placebo in the treatment of…
- Trial name
- NCT00571675
- Testing
- AT-101, prednisone and docetaxel
- Where
- 35 sites in United States, Russia
- Volunteers
- 220 people
- Sponsor
- Ascenta Therapeutics
Prostate Cancer
Immunotherapy After Chemotherapy for Patients With Hormone Refractory Metastatic Prostate Cancer
The purpose of this study is to test if interleukin-2, a drug that stimulates the immune system, can be used after chemotherapy to slow the progression of your disease.
- Trial name
- NCT00283829
- Testing
- docetaxel, IL2
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Washington
Advanced Malignancy, Advanced Solid Tumors
A Dose Escalation Study of SDX-7320 in Patients With Advanced Refractory or Late-Stage Solid Tumors
This is a Phase 1 dose escalation to assess the safety, tolerability and maximum tolerated dose of subcutaneous administered SDX-7320 in patients with advanced refractory or late-stage solid tumors.
- Conditions
- Advanced Malignancy, Advanced Solid Tumors, Neoplasm, Metastasis
- Trial name
- SDX-0101 (NCT02743637)
- Testing
- SDX-7320
- Where
- 3 sites in United States
- Volunteers
- 32 people
- Sponsor
- SynDevRx, Inc.
Cancer
Care of Cancer Patients With Bowel Injury Caused by Radiation Therapy to the Pelvis
RATIONALE: A step-by-step procedure may help health care practitioners diagnose and treat cancer patients with bowel injury symptoms caused by radiation therapy.
- Trial name
- NCT00737230
- Testing
- educational intervention, questionnaire administration, assessment of therapy complications
- Where
- United Kingdom
- Volunteers
- 250 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Metastatic Prostate Cancer, Recurrent Prostate Cancer
Impact of Atorvastatin on Prostate Cancer Progression During ADT
This randomized double-blind placebo-controlled trial tests whether intervention with atorvastatin delays development of castration resistance compared to placebo during androgen deprivation therapy (ADT) for prostate cancer.
- Trial name
- ESTO2 (NCT04026230)
- Testing
- Atorvastatin 80mg
- Where
- 10 sites in Denmark, Estonia and 2 more
- Volunteers
- 400 people
- Sponsor
- Tampere University Hospital
Leukemia, Lung Cancer
Phenylbutyrate Plus Azacitidine in Treating Patients With Acute Myeloid Leukemia, Myelodysplasia, Non-Hodgkin's Lymphoma, Multiple Myeloma, Non-small Cell Lung Cancer, or Prostate Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one chemotherapy drug may kill more cancer cells.
- Conditions
- Leukemia, Lung Cancer, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00006019
- Testing
- azacitidine, sodium phenylbutyrate
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Prostate Cancer Metastatic
Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Docetaxel and cabazitaxel are cancer chemotherapy agents of the taxane drug class. The purpose of this study is to explore the benefit, for treatment of metastatic castration-resistant prostate cancer (mCRPC), of a regimen in…
- Trial name
- TAXYNERGY (NCT01718353)
- Testing
- DOCETAXEL (XRP6976), CABAZITAXEL (XRP6258), Prednisone
- Where
- 19 sites in United States, Canada
- Volunteers
- 63 people
- Sponsor
- Sanofi
Prostate Cancer
A Phase Ib Study of Intravenous Copper Loading With Oral Disulfiram in Metastatic, Castration Resistant Prostate Cancer
The purpose of this study is to determine the safety and optimal dosing of intravenous copper chloride and disulfiram in men with metastatic castrate-resistant prostate cancer (CRPC).
- Trial name
- NCT02963051
- Testing
- Copper, Disulfiram, Copper gluconate
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Daniel George, MD
Fatigue, Metastatic Prostate Carcinoma
Resistance Training +/- Creatine for Metastatic Prostate Cancer Patients
This trial studies how well resistance training with or without creatine monohydrate supplement works in improving body composition and health outcomes in patients with prostate cancer that has spread to other places in the body.
- Conditions
- Fatigue, Metastatic Prostate Carcinoma, Sedentary Lifestyle, Stage IV Prostate Cancer AJCC (American Joint Committee on Cancer) v8
- Trial name
- NCT03987217
- Testing
- Creatine Monohydrate, Exercise Intervention, Questionnaire Administration
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- University of Utah
Cancer, Breast Cancer
A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors
The purpose of this study is to characterize the safety and tolerability of ALTA2618 in adults with AKT1 E17K-mutant advanced solid tumors.
- Conditions
- Cancer, Breast Cancer, Endometrial Cancer, Metastatic Cancer
- Trial name
- NCT06533059
- Testing
- ALTA2618
- Where
- 31 sites in United States, Australia and 6 more
- Volunteers
- 110 people
- Sponsor
- Alterome Therapeutics, Inc.
Prostate Cancer Metastatic
Study of VERU-944 to Ameliorate Hot Flashes in Men With Advanced Prostate Cancer
Randomized, double-blind, placebo controlled, dose finding Phase 2 study comparing oral daily dosing of VERU-944 after a week of loading (daily dosing) with placebo to ameliorate the vasomotor symptoms resulting from androgen…
- Trial name
- NCT03646162
- Testing
- Veru-944
- Where
- 24 sites in United States
- Volunteers
- 93 people
- Sponsor
- Veru Inc.
Prostate Cancer
Clonal Emergence and Regression During Radium-223 Therapy for Metastatic Prostate Cancer
This study is for patients with metastatic prostate cancer receiving radium-223 as their standard of care therapy. The researchers will collect blood and urine samples from patients before, during and after the radium-223…
- Trial name
- NCT03677076
- Testing
- Ancillary/Correlative
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Medical University of South Carolina
Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostatic Neoplasms
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
The purpose of this study is to assess the efficacy and safety of opevesostat plus daily corticosteroids compared to alternative abiraterone acetate or enzalutamide in participants with Metastatic Castration-resistant Prostate…
- Trial name
- NCT06136650
- Testing
- Opevesostat, Dexamethasone, Fludrocortisone acetate
- Where
- 330 sites in United States, Australia and 37 more
- Volunteers
- 1,314 people
- Sponsor
- Merck Sharp & Dohme LLC